Can fat cell therapy help Normal-Weight diabetics?

NCT ID NCT06657209

Recruiting now Disease control Sponsor: Stanford University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how fat cells work differently in normal-weight people with type 2 diabetes compared to those without diabetes. Researchers will test two drugs, pioglitazone and tirzepatide, to see if they improve insulin resistance and fat storage. About 104 adults aged 30-70 will participate over 16 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pioglitazone and tirzepatide (Mounjaro)
What this could lead to: If successful, this could point toward better treatment options for normal-weight people with type 2 diabetes, a group often overlooked in research.
What could go wrong: This is a small, early-phase study with only 104 participants. Results may not apply to everyone, and the drugs have known side effects like weight gain (pioglitazone) or gastrointestinal issues (tirzepatide).

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus glucose intolerance Insulin Resistance prediabetes syndrome type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES DIABETES MELLITUS, TYPE 2 PRE-DIABETES TYPE 2 DIABETES

Contacts and locations

Locations

Stanford University
RECRUITING

Palo Alto, California, 94304, United States
Stanford University, Clinical and Translational Research Unit (CTRU)
NOT_YET_RECRUITING

Stanford, California, 94304, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.